Keyword: Akebia Therapeutics
Though the Japanese data aren’t a perfect predictor for vadadustat’s global registrational studies, Piper Jaffray analysts called them “a nice proxy."
The combined company will own potentially complementary kidney disease drugs and a sales force to promote them.
Alexion bids farewell to CFO, CCO, R&D head and HR chief; Illumina's interim CCO became permanent; INC Research unveiled new executive team.
Vifor Pharma has struck a deal to sell Akebia Therapeutics’ phase 3 oral anemia drug vadadustat through its network of U.S. dialysis centers.
Otsuka Pharmaceutical has expanded its anemia pact with Akebia Therapeutics.
GlaxoSmithKline has one of the lowest R&D budgets in percentage of revenue terms of its peers; although its research budget was slightly up on 2015, this is still markedly down from the around £4 billion it was spending in 2012-13.
Johnson & Johnson has outlicensed its portfolio of hypoxia-inducible factor to Cambridge MA-based Akebia as the biotech boosts its early-stage pipeline.
Authorities have arrested Merrimack Pharmaceuticals’ director of statistical programming for allegedly leaking tips about upcoming trial data.
Akebia's determination to self-develop its anemia drug vadadustat in the U.S. has been overturned by a not-to-be-missed deal with Otsuka valued at up to $1 billion.